The first poster includes positive Investigational New Drug (IND)-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212 Pb for small cell lung cancer patients. The second ...

DLL3 is a promising target for radioligand therapy ... while not expressed in healthy tissues. Pb Radio-DARPin poster outlines how MSLN may be a promising target for ovarian cancer due to its ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical ...

ZW209, a DLL3 targeted trispecific T cell engager with ... Additionally, Zymeworks scientists co-authored two poster presentations focused on leveraging technologies that support the design ...

These include: (1) a poster presentation of Abdera’s ongoing Phase 1 clinical trial for ABD-147, a DLL3-targeting radiopharmaceutical, and (2) preclinical data on ABD-320, a 5T4-targeting ...

In a deal valued at up to $1 billion, Roche has licensed rights to a DLL3-directed antibody-drug conjugate (ADC) from China's Innovent Biologics, hoping to bring a competitor to Amgen's recently ...

DLL3 is a promising target for radioligand therapy ... The MSLN x 212Pb Radio-DARPin poster outlines how MSLN may be a promising target for ovarian cancer due to its differentiated expression ...

Delta-like ligand (DLL3) antibody-drug conjugate (ADC) for the treatment of extensive-stage small cell lung cancer (ES-SCLC), will be presented during a poster session at the 2025 American Society ...

First preclinical data of novel targeted Radio-DARPin against mesothelin (MSLN), in co-development with Orano Med "Our presentations at AACR highlight the breadth of Molecular Partners' DARPin ...